相关临床试验
0
0 进行中
药物批准
25
批准总数
监管机构
1
监管机构数
成立时间
1987
暂无试验阶段数据
暂无试验数据
暂无试验数据
- MSD (Merck & Co.) has secured non-exclusive global rights to Cyprumed's oral peptide delivery platform, potentially transforming injectable peptide treatments into convenient tablet formulations. - The agreement includes up to $493 million in milestone payments and grants MSD options for exclusive licensing of the technology for specific targets, with MSD leading all development and commercialization efforts. - Cyprumed's innovative tablet formulation technology offers superior bioavailability using approved pharmaceutical excipients, potentially advancing MSD's macrocyclic peptide portfolio including enlicitide decanoate and efinopegdutide.
- UCB's Bimzelx Navigate program offers bridge access to therapy at $15 per dose for up to 2 years, addressing insurance coverage delays for commercially insured patients. - The program features a dedicated nurse navigator system providing personalized support for insurance, injection training, and emotional support, while maintaining connection with treating physicians. - A digital patient portal and copay assistance program reducing costs to $5 per dose for eligible patients complete the holistic support ecosystem.
